Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic Cancer

Loading news article.

Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic Cancer | WAPE

Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic Cancer

Article summary

Related companies

Comments —